Fate Therapeutics, Inc. (FATE)

3.8000 -0.0700 (-1.81%) 收市：04:00PM EDT

Fate Therapeutics, Inc.

12278 Scripps Summit Drive
San Diego, CA 92131
United States
858 875 1800
https://www.fatetherapeutics.com

版塊: Healthcare
行業: Biotechnology
全職員工: 181

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. J. Scott Wolchko	Founder, CEO, President & Director	645k	3.85M	1970
Mr. Edward J. Dulac III	Chief Financial Officer	455k	無	1976
Ms. Cindy R. Tahl J.D.	General Counsel, Corporate Secretary & Compliance Officer	455k	3.89M	1973
Dr. Bahram Valamehr Ph.D.	Chief Research & Development Officer	455k	1.39M	1977
Mr. Jim Beitel M.B.A.	Senior Vice President of Corporate Development	無	無	無
Dr. Jerome Bressi Ph.D.	Senior Vice President of Regulatory & Quality	無	無	無
Dr. Barbara Hickingbottom	Senior VP of Clinical Development	無	無	無

截止 2022年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

公司管治

截至 2024年4月1日 止，Fate Therapeutics, Inc. 的 ISS 管治質素評分為 7。 Pillar 分數正在審核中：8；董事會：5；股東權利：8；現金賠償：7。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。